摘要
近年来许多研究证实了非编码RNA在调整基因表达方面的重要作用。研究主要集中于短非编码基因,如miRNAs,而长非编码RNA(lncRNA)现对来说研究较少。长非编码基因能从基因间,基因内或特殊染色体区域进行转录。与miRNAs相比,lncRNAs有复杂的二级和三级结构,使得它们能连接蛋白质,RNA,DNA和执行基础功能。许多研究表明细胞外ncRNAs在正常人和病人血液中都能循环。大部分参与循环的ncRNAs都分布在使它们高度稳定的脂质或者脂蛋白囊泡中,如凋亡小体,大多孔脂质体或者外来体。癌症病人与正常人血液中参与循环的ncRNAs可能成为新的诊断标记物。HOTAIR是同源框蛋白转录反义RNA,存在于HOXC核心区,它能够抑制HOXD核心区转录后期。HOTAIR参与了许多主要肿瘤的演变,HOTAIR的表达能促进(肿瘤)入侵和转移。这篇综述描述了lncRNA HOTAIR可能成为参与循环的标记物的实验证据。
关键词: 长非编码RNA,HOTAIR,参与循环的长非编码RNA,癌症,血液
Current Drug Targets
Title:LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Volume: 18 Issue: 1
Author(s): Gerardo Botti, Laura Marra, Maria Gabriella Malzone, Annamaria Anniciello, Chiara Botti, Renato Franco, Monica Cantile
Affiliation:
关键词: 长非编码RNA,HOTAIR,参与循环的长非编码RNA,癌症,血液
摘要: In the recent years the importance of the role played by non-coding RNA on the regulation of gene expression was increased by numerous studies. The research mainly focused on small ncRNAs, such as miRNAs, while the functions of long non-coding RNA (lncRNA) have been much less studied. lncRNAs can be transcribed from intergenic, intragenic or specific chromosomal regions. Compared to miRNAs, lncRNAs have a complex secondary and tertiary structure which allows to bind proteins, RNA, DNA and to carry out their regulatory functions. Several studies showed that extracellular ncRNAs can circulate in the blood of both healthy and diseased patients. Most of the circulating ncRNAs are included in lipid or lipoprotein vesicles, such as apoptotic bodies, macrovesicles or exosomes, in which they are highly stable. The presence of circulating ncRNAs in the blood of cancer patients versus normal subjects suggested the possibility that these molecules may represent new diagnostic markers. HOTAIR is a HOX transcript antisense RNA, located in the HOXC locus, able to repress transcription in the posterior region of the HOXD locus. HOTAIR has been <involved in the evolution of several primary tumors, wherein increase of HOTAIR expression has endorsed invasion and metastasis. In this review, we describe the experimental evidences on the potential role as circulating marker of lncRNA HOTAIR.
Export Options
About this article
Cite this article as:
Gerardo Botti, Laura Marra, Maria Gabriella Malzone, Annamaria Anniciello, Chiara Botti, Renato Franco, Monica Cantile , LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases, Current Drug Targets 2017; 18 (1) . https://dx.doi.org/10.2174/1389450117666151209122950
DOI https://dx.doi.org/10.2174/1389450117666151209122950 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Current Management of Chordoma
Current Drug Therapy Perspectives in Tissue Microarrays
Combinatorial Chemistry & High Throughput Screening The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Leucine-zipper and Sterile-α Motif Kinase (ZAK): A Potential Target for Drug Discovery
Current Medicinal Chemistry Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design Targeted Delivery of Therapeutics to Urological Cancer Stem Cells
Current Pharmaceutical Design Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment
Current Pharmaceutical Design Linking New Paradigms in Protein Chemistry to Reversible Membrane-Protein Interactions
Current Protein & Peptide Science Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Current Topics in Medicinal Chemistry Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic
Current Pharmaceutical Design The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy KSP Inhibitors as Antimitotic Agents
Current Topics in Medicinal Chemistry Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design Gold Nanoparticle Based Systems in Genetics
Current Pharmacogenomics